BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504. [PMID: 8133533 DOI: 10.1093/jnci/86.7.499] [Cited by in Crossref: 311] [Cited by in F6Publishing: 299] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Shibata H, Matsubara O. Apoptosis as an independent prognostic indicator in squamous cell carcinoma of the esophagus. Pathol Int 2001;51:498-503. [PMID: 11472561 DOI: 10.1046/j.1440-1827.2001.01234.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
2 Reed JC, Zha H, Aime-sempe C, Takayama S, Wang H. Structure—Function Analysis of Bcl-2 Family Proteins. In: Gupta S, Cohen JJ, editors. Mechanisms of Lymphocyte Activation and Immune Regulation VI. Boston: Springer US; 1996. pp. 99-112. [DOI: 10.1007/978-1-4899-0274-0_10] [Cited by in Crossref: 141] [Cited by in F6Publishing: 91] [Article Influence: 5.6] [Reference Citation Analysis]
3 Cardoso F, Paesmans M, Larsimont D, Durbecq V, Bernard-marty C, Rouas G, Dolci S, Sotiriou C, Piccart MJ, Di Leo A. Potential Predictive Value of Bcl-2 for Response to Tamoxifen in the Adjuvant Setting of Node-Positive Breast Cancer. Clinical Breast Cancer 2004;5:364-9. [DOI: 10.3816/cbc.2004.n.043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Götz C, Montenarh M. p53: DNA damage, DNA repair, and apoptosis. Reviews of Physiology, Biochemistry and Pharmacology, Volume 94. Berlin: Springer Berlin Heidelberg; 1982. pp. 65-95. [DOI: 10.1007/bfb0048265] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
5 Zhai YL, Nikaido T, Toki T, Shiozawa A, Orii A, Fujii S. Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus. Br J Cancer 1999;80:1658-64. [PMID: 10408415 DOI: 10.1038/sj.bjc.6690578] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.1] [Reference Citation Analysis]
6 Zhou F, Yang Y, Xing D. Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J 2011;278:403-13. [PMID: 21182587 DOI: 10.1111/j.1742-4658.2010.07965.x] [Cited by in Crossref: 262] [Cited by in F6Publishing: 255] [Article Influence: 23.8] [Reference Citation Analysis]
7 Bruckheimer EM, Cho SH, Sarkiss M, Herrmann J, McDonnell TJ. The Bcl-2 gene family and apoptosis. Adv Biochem Eng Biotechnol 1998;62:75-105. [PMID: 9755641 DOI: 10.1007/BFb0102306] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 0.2] [Reference Citation Analysis]
8 Shpitz B, Tiomkin V, Bomstein Y, Gralkin M, Buklan H, Bernheim J, Klein E. Evaluation of putative molecular biomarkers in abdominal and retroperitoneal leiomyosarcomas. European Journal of Surgical Oncology (EJSO) 2001;27:203-8. [DOI: 10.1053/ejso.2000.1074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
9 Mclaughlin R, O’hanlon D, Mchale T, Connolly CE, Given HF. Prognostic implications of p53 and bcl-2 expression in 108 women with stage two breast cancer. Ir J Med Sci 2001;170:11-3. [DOI: 10.1007/bf03167712] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
10 Bevilacqua A, Ceriani MC, Canti G, Asnaghi L, Gherzi R, Brewer G, Papucci L, Schiavone N, Capaccioli S, Nicolin A. Bcl-2 Protein Is Required for the Adenine/Uridine-rich Element (ARE)-dependent Degradation of Its Own Messenger. Journal of Biological Chemistry 2003;278:23451-9. [DOI: 10.1074/jbc.m210620200] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
11 Froesch BA, Aimé-Sempé C, Leber B, Andrews D, Reed JC. Inhibition of p53 transcriptional activity by Bcl-2 requires its membrane-anchoring domain. J Biol Chem 1999;274:6469-75. [PMID: 10037739 DOI: 10.1074/jbc.274.10.6469] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 1.6] [Reference Citation Analysis]
12 Chen Y, Lui HM, Lin S, Lee JM, Ying S. Regulation of Cell Proliferation, Apoptosis, and Carcinogenesis by Activin. Exp Biol Med (Maywood) 2002;227:75-87. [DOI: 10.1177/153537020222700201] [Cited by in Crossref: 153] [Cited by in F6Publishing: 144] [Article Influence: 30.6] [Reference Citation Analysis]
13 Molino A, Giovannini M, Auriemma A, Fiorio E, Mercanti A, Mandarà M, Caldara A, Micciolo R, Pavarana M, Cetto GL. Pathological, biological and clinical characteristics, and surgical management, of elderly women with breast cancer. Crit Rev Oncol Hematol 2006;59:226-33. [PMID: 16533603 DOI: 10.1016/j.critrevonc.2006.01.007] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
14 Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Lavaut MN, Allasia C. Automated and quantitative immunocytochemical assays of Bcl-2 protein in breast carcinomas. Br J Cancer 1997;76:340-6. [PMID: 9252201 DOI: 10.1038/bjc.1997.388] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
15 Lee AK, Loda M, Mackarem G, Bosari S, Delellis RA, Heatley GJ, Hughes K. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bN0M0): Clinicopathologic features and outcome. Cancer 1997;79:761-71. [DOI: 10.1002/(sici)1097-0142(19970215)79:4<761::aid-cncr13>3.0.co;2-y] [Cited by in Crossref: 49] [Article Influence: 2.0] [Reference Citation Analysis]
16 Eerola A, Ruokolainen H, Soini Y, Raunio H, Pääkkö P. Accelerated apoptosis and low Bcl-2 expression associated with neuroendocrine differentiation predict shortened survival in operated large cell carcinoma of the lung. Pathol Oncol Res 1999;5:179-86. [DOI: 10.1053/paor.1999.0198] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
17 Veneroni S, Silvestrini R, Costa A, Salvatori P, Faranda A, Molinari R. Biological indicators of survival in patients treated by surgery for squamous cell carcinoma of the oral cavity and oropharynx. Oral Oncology 1997;33:408-13. [DOI: 10.1016/s0964-1955(97)00036-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 López-Otín C, Diamandis EP. Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev. 1998;19:365-396. [PMID: 9715372 DOI: 10.1210/edrv.19.4.0337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 38] [Article Influence: 0.1] [Reference Citation Analysis]
19 Silvestrini R, Daidone MG, Veneroni S, Benini E, Scarfone G, Zanaboni F, Villa A, Presti M, Danese S, Bolis G. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Cancer 1998;82:159-67. [DOI: 10.1002/(sici)1097-0142(19980101)82:1<159::aid-cncr20>3.0.co;2-0] [Cited by in Crossref: 27] [Article Influence: 1.2] [Reference Citation Analysis]
20 Nadler Y, Camp RL, Giltnane JM, Moeder C, Rimm DL, Kluger HM, Kluger Y. Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res 2008;10:R35. [PMID: 18430249 DOI: 10.1186/bcr1998] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
21 Geuna M, Palestro G, Malandrone LB, Durando A, Demurtas A, Torchio B, Massobrio M. Relationships between Proliferative Activity and Oncogene Expression in Human Breast Cancer. Ann NY Acad Sci 1996;784:555-63. [DOI: 10.1111/j.1749-6632.1996.tb16280.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
22 Turner BC, Krajewski S, Krajewska M, Takayama S, Gumbs AA, Carter D, Rebbeck TR, Haffty BG, Reed JC. BAG-1: a novel biomarker predicting long-term survival in early-stage breast cancer. J Clin Oncol. 2001;19:992-1000. [PMID: 11181661 DOI: 10.1200/JCO.2001.19.4.992] [Cited by in Crossref: 66] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
23 Ofner D, Riehemann K, Maier H. Immunohistochemically detected bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer. 1995;72:981-985. [PMID: 7547253 DOI: 10.1038/bjc.1995.446] [Cited by in Crossref: 85] [Cited by in F6Publishing: 94] [Article Influence: 3.3] [Reference Citation Analysis]
24 Rolland P, Spendlove I, Madjid Z, Rakha EA, Patel P, Ellis IO, Durrant L. The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. Int J Cancer 2007;120:1311-7. [DOI: 10.1002/ijc.22430] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
25 Tang S, Shaheta N, Chernenko G, Khalifa M, Wang X. Expression of BAG-1 in Invasive Breast Carcinomas. JCO 1999;17:1710-1710. [DOI: 10.1200/jco.1999.17.6.1710] [Cited by in Crossref: 53] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
26 Al-Moundhri M, Nirmala V, Al-Mawaly K, Ganguly S, Burney I, Rizvi A, Grant C. Significance of p53, Bcl-2, and HER-2/neu protein expression in Omani Arab females with breast cancer. Pathol Oncol Res 2003;9:226-31. [PMID: 14688828 DOI: 10.1007/BF02893382] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
27 Siziopikou KP, Khan S. Correlation of HER2 Gene Amplification With Expression of the Apoptosis-Suppressing Genes bcl-2 and bcl-x-L in Ductal Carcinoma in Situ of the Breast: . Applied Immunohistochemistry & Molecular Morphology 2005;13:14-8. [DOI: 10.1097/00129039-200503000-00003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
28 Hesch R, Kenemans P. Hormonal prevention of breast cancer: proposal for a change in paradigm. BJOG:An international journal of O&G 1999;106:1006-18. [DOI: 10.1111/j.1471-0528.1999.tb08106.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
29 Szostak MJ, Kaur P, Amin P, Jacobs SC, Kyprianou N. Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. J Urol. 2001;165:2126-2130. [PMID: 11371940 DOI: 10.1016/s0022-5347(05)66306-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
30 Vollmer RT, Humphrey PA, Swanson PE, Wick MR, Hudson ML. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. Cancer 1998;82:715-23. [PMID: 9477105 DOI: 10.1002/(sici)1097-0142(19980215)82:4<715::aid-cncr15>3.0.co;2-0] [Cited by in Crossref: 57] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
31 Pezzella F, Di Bacco A, Andreola S, Nicholson A, Pastorino U, Harris A. Angiogenesis in primary lung cancer and lung secondaries. European Journal of Cancer 1996;32:2494-500. [DOI: 10.1016/s0959-8049(96)00377-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
32 Binder C, Marx D, Binder L, Schauer A, Hiddemann W. Expression of Bax in relation to Bcl-2 and other predictive parameters in breast cancer. Ann Oncol 1996;7:129-33. [PMID: 8777167 DOI: 10.1093/oxfordjournals.annonc.a010538] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 1.3] [Reference Citation Analysis]
33 Pena JC, Thompson CB, Recant W, Vokes EE, Rudin CM. Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer 1999;85:164-70. [DOI: 10.1002/(sici)1097-0142(19990101)85:1<164::aid-cncr23>3.0.co;2-q] [Cited by in Crossref: 81] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
34 Lee HK, Lee HS, Yang HK, Kim WH, Lee KU, Choe KJ, Kim JP. Prognostic significance of Bcl-2 and p53 expression in gastric cancer. Int J Colorectal Dis. 2003;18:518-525. [PMID: 12811476 DOI: 10.1007/s00384-003-0491-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 1.8] [Reference Citation Analysis]
35 Hwang KT, Han W, Kim J, Moon HG, Oh S, Song YS, Kim YA, Chang MS, Noh DY. Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer. J Breast Cancer 2017;20:54-64. [PMID: 28382095 DOI: 10.4048/jbc.2017.20.1.54] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
36 Watatani M, Ieda S, Kuroda K, Inui H, Nishimura K, Yasutomi M. Comparison of p53 and bcl-2 expression in initial, synchronous, and metachronous colorectal adenomas. Surg Today 1999;29:707-12. [PMID: 10483743 DOI: 10.1007/BF02482313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 González-cámpora R, Ruiz MRG, Ramírez FV, Martín JJR, Santos JMF, Martos MDMR, Pascual AG. Apoptosis in Breast Carcinoma. Pathology - Research and Practice 2000;196:167-74. [DOI: 10.1016/s0344-0338(00)80097-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
38 Waggoner SE, Baunoch DA, Anderson SA, Leigh F, Zagaja VG. Bcl-2 protein expression associated with resistance to apoptosis in clear cell adenocarcinomas of the vagina and cervix expressing wild-type p53. Annals of Surgical Oncology 1998;5:544-7. [DOI: 10.1007/bf02303648] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
39 Jäättelä M. Escaping cell death: survival proteins in cancer. Exp Cell Res. 1999;248:30-43. [PMID: 10094811 DOI: 10.1006/excr.1999.4455] [Cited by in Crossref: 448] [Cited by in F6Publishing: 424] [Article Influence: 20.4] [Reference Citation Analysis]
40 Arya V, Singh S, Daniel MJ. Clinicopathological correlation of Bcl-2 oncoprotein expression in oral precancer and cancer. J Oral Biol Craniofac Res 2016;6:18-23. [PMID: 26937364 DOI: 10.1016/j.jobcr.2015.12.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
41 Nishimura A. Changes in Bcl-2 and Bax Expression in Rat Tongue during 4-Nitroquinoline 1-oxide-induced Carcinogenesis. J Dent Res 1999;78:1264-9. [DOI: 10.1177/00220345990780061101] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
42 Müller-Höcker J. Immunoreactivity of p53, Ki-67, and Bcl-2 in oncocytic adenomas and carcinomas of the thyroid gland. Hum Pathol 1999;30:926-33. [PMID: 10452505 DOI: 10.1016/s0046-8177(99)90246-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
43 Kapucuoglu N, Losi L, Eusebi V. Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive duct breast carcinomas. Virchows Arch 1997;430:17-22. [PMID: 9037310 DOI: 10.1007/BF01008011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
44 Sarbia M, Bittinger F, Porschen R, Verreet P, Dutkowski P, Willers R, Gabbert HE. bcl-2 expression and prognosis in squamous-cell carcinomas of the esophagus. Int J Cancer 1996;69:324-8. [DOI: 10.1002/(sici)1097-0215(19960822)69:4<324::aid-ijc15>3.0.co;2-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
45 van Slooten HJ, van de Vijver MJ, van de Velde CJ, van Dierendonck JH. Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer 1998;77:789-96. [PMID: 9514059 DOI: 10.1038/bjc.1998.128] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 2.3] [Reference Citation Analysis]
46 Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene. 2008;27:6398-6406. [PMID: 18955968 DOI: 10.1038/onc.2008.307] [Cited by in Crossref: 557] [Cited by in F6Publishing: 510] [Article Influence: 42.8] [Reference Citation Analysis]
47 Khoo US, Leong AS. Biologic Markers in Breast Cancer: An Update. Journal of Histotechnology 2013;21:317-25. [DOI: 10.1179/his.1998.21.4.317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 Sheridan MT, O'dwyer T, Seymour CB, Mothersill CE. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig 1997;5:180-6. [DOI: 10.1002/(sici)1520-6823(1997)5:4<180::aid-roi3>3.0.co;2-u] [Cited by in Crossref: 108] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
49 Eissa S, Labib R, Khalifa A, Swelam N, Khalil F, El-Shenawy AM. Regulators of apoptosis in human breast cancer. Clin Biochem 1999;32:321-6. [PMID: 10480445 DOI: 10.1016/s0009-9120(99)00025-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
50 Diaz-cano SJ, Garcia-moliner M, Carney W, Wolfe HJ. Bcl-2 Expression and DNA Fragmentation in Breast Carcinoma, Pathologic and Steroid Hormone Receptors Correlates: . Diagnostic Molecular Pathology 1997;6:199-208. [DOI: 10.1097/00019606-199708000-00004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
51 Martin B, Paesmans M, Berghmans T, Branle F, Ghisdal L, Mascaux C, Meert AP, Steels E, Vallot F, Verdebout JM. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2003;89:55-64. [PMID: 12838300 DOI: 10.1038/sj.bjc.6601095] [Cited by in Crossref: 106] [Cited by in F6Publishing: 95] [Article Influence: 5.9] [Reference Citation Analysis]
52 Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: A study of a large cohort of patients treated with surgery alone. Cancer 2004;100:2317-27. [DOI: 10.1002/cncr.20260] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 4.4] [Reference Citation Analysis]
53 Kaiser U, Schilli M, Haag U, Neumann K, Kreipe H, Kogan E, Havemann K. Expression of bcl-2--protein in small cell lung cancer. Lung Cancer 1996;15:31-40. [PMID: 8865121 DOI: 10.1016/0169-5002(96)00568-5] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 2.3] [Reference Citation Analysis]
54 Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res. 2008;87:14-32. [PMID: 18096889 DOI: 10.1177/154405910808700104] [Cited by in Crossref: 259] [Cited by in F6Publishing: 236] [Article Influence: 19.9] [Reference Citation Analysis]
55 Margolin K, Synold TW, Lara P, Frankel P, Lacey SF, Quinn DI, Baratta T, Dutcher JP, Xi B, Diamond DJ, Gandara DR. Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. J Cancer Res Clin Oncol 2007;133:705-11. [PMID: 17508219 DOI: 10.1007/s00432-007-0200-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
56 Ceccarelli C, Santini D, Chieco P, Taffurelli M, Marrano D, Mancini A. Multiple expression patterns of biopathological markers in primary invasive breast carcinoma: A useful tool for elucidating its biological behaviour. Annals of Oncology 1995;6:275-82. [DOI: 10.1093/oxfordjournals.annonc.a059158] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
57 Huang CI, Neuberg D, Johnson BE, Wei JY, Christiani DC. Expression ofbcl-2 protein is associated with shorter survival in nonsmall cell lung carcinoma. Cancer 2003;98:135-43. [DOI: 10.1002/cncr.11461] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
58 Diratzouian H, Freedman GM, Hanlon AL, Eisenberg DF, Anderson PR. Importance of physical examination in the absence of a mammographic abnormality for the detection of early-stage breast cancer. Clin Breast Cancer 2005;6:330-3. [PMID: 16277883 DOI: 10.3816/CBC.2005.n.036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Szostak MJ, Kaur P, Amin P, Jacobs SC, Kyprianou N. Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. J Urol 2001;165:2126-30. [PMID: 11371940 DOI: 10.1097/00005392-200106000-00082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
60 Ferrandina G, Mozzetti S, Marone M, Fagotti A, Macchia G, Mancuso S, Scambia G. Bcl-2, bax, bcl-xL and bcl-xS expression in neoplastic and normal cervical tissue. Cancer Letters 2000;155:19-27. [DOI: 10.1016/s0304-3835(00)00393-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
61 Chittenden T. Mammalian bcl-2 family genes. Apoptosis Genes. Boston: Springer US; 1999. pp. 37-84. [DOI: 10.1007/978-1-4615-5287-1_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
62 Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S, López-berestein G, Andreeff M. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 2000;95:3929-38. [DOI: 10.1182/blood.v95.12.3929.012k01_3929_3938] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
63 Dai X, Xiang L, Li T, Bai Z. Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. J Cancer. 2016;7:1281-1294. [PMID: 27390604 DOI: 10.7150/jca.13141] [Cited by in Crossref: 138] [Cited by in F6Publishing: 131] [Article Influence: 27.6] [Reference Citation Analysis]
64 Zhuang XQ, Yuan SZ, Wang XH, Lai RQ, Luo ZQ. Oncoprotein expression and inhibition of apoptosis during colorectal tumorigenesis. World J Gastroenterol 1996; 2(1): 3-5 [DOI: 10.3748/wjg.v2.i1.3] [Reference Citation Analysis]
65 Cheng N, van de Wetering CI, Knudson CM, Klefstrom J. p27 Deficiency Cooperates with Bcl-2 but Not Bax to Promote T-Cell Lymphoma. PLoS ONE 2008;3:e1911. [DOI: 10.1371/journal.pone.0001911] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
66 McDonald FE, Ironside JW, Gregor A, Wyatt B, Stewart M, Rye R, Adams J, Potts HW. The prognostic influence of bcl-2 in malignant glioma. Br J Cancer 2002;86:1899-904. [PMID: 12085183 DOI: 10.1038/sj.bjc.6600217] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
67 Simon R, Mirlacher M, Sauter G. Tissue microarrays for early target evaluation. Drug Discovery Today: Technologies 2004;1:41-8. [DOI: 10.1016/j.ddtec.2004.08.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
68 Tsuda H, Sakamaki C, Tsugane S, Fukutomi T, Hirohashi S. Prognostic Significance of Accumulation of Gene and Chromosome Alterations and Histological Grade in Node-negative Breast Carcinoma. Japanese Journal of Clinical Oncology 1998;28:5-11. [DOI: 10.1093/jjco/28.1.5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
69 Van Nguyen C, Nguyen QT, Vu HTN, Phung HT, Pham KH, Le RD. Combined p53 and Bcl2 Immunophenotypes in Prognosis of Vietnamese Invasive Breast Carcinoma: A Single Institutional Retrospective Analysis. Technol Cancer Res Treat 2020;19:1533033820983081. [PMID: 33357134 DOI: 10.1177/1533033820983081] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: Importance of prognostic markers of the primary tumor. Cancer 2003;97:545-53. [DOI: 10.1002/cncr.11083] [Cited by in Crossref: 186] [Cited by in F6Publishing: 168] [Article Influence: 10.3] [Reference Citation Analysis]
71 Ménard S, Casalini P, Tomasic G, Pilotti S, Cascinelli N, Bufalino R, Perrone F, Longhi C, Rilke F, Colnaghi MI. Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res Treat 1999;55:167-75. [DOI: 10.1023/a:1006262324959] [Cited by in Crossref: 31] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
72 Lanzafame S, Emmanuele C, Torrisi A, Magro G. Correlated Expression of BCL-2 Protein, Estrogen Receptor, Cathepsin D and Low Growth Fraction (PCNA) in Intracystic Papillary Breast Carcinoma. Pathology - Research and Practice 1998;194:541-7. [DOI: 10.1016/s0344-0338(98)80043-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
73 Hemachandran M, Nijhawan R, Joshi K. Cytological grading, apoptosis, and Bcl-2 protein expression in breast cancer. Diagn Cytopathol 2002;26:356-9. [DOI: 10.1002/dc.10105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
74 Daidone MG, Luisi A, Martelli G, Benini E, Veneroni S, Tomasic G, De Palo G, Silvestrini R. Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women. Br J Cancer 2000;82:270-7. [PMID: 10646876 DOI: 10.1054/bjoc.1999.0914] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.1] [Reference Citation Analysis]
75 Dimitrakakis C, Konstadoulakis M, Messaris E, Kymionis G, Karayannis M, Panoussopoulos D, Michalas S, Androulakis G. Molecular markers in breast cancer: can we use c-erbB-2, p53, bcl-2 and bax gene expression as prognostic factors? Breast. 2002;11:279-285. [PMID: 14965683 DOI: 10.1054/brst.2002.0445] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
76 Trask DK, Wolf GT, Bradford CR, Fisher SG, Devaney K, Johnson M, Singleton T, Wicha M. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope 2002;112:638-44. [PMID: 12150516 DOI: 10.1097/00005537-200204000-00009] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 3.8] [Reference Citation Analysis]
77 Marshall J, Chen H, Yang D, Figueira M, Bouker KB, Ling Y, Lippman M, Frankel SR, Hayes DF. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 2004;15:1274-83. [PMID: 15277270 DOI: 10.1093/annonc/mdh317] [Cited by in Crossref: 51] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
78 Lin HM, Lee YJ, Li G, Pestell RG, Kim HR. Bcl-2 induces cyclin D1 promoter activity in human breast epithelial cells independent of cell anchorage. Cell Death Differ 2001;8:44-50. [PMID: 11313702 DOI: 10.1038/sj.cdd.4400770] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
79 Park C, Park K, Kim J, Sin Y, Park I, Cho H, Yang K, Bae BN, Kim KW, Ahn S, Gwak G. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer. World J Surg Oncol. 2016;14:244. [PMID: 27619909 DOI: 10.1186/s12957-016-0999-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
80 Manne U, Myers RB, Moron C, Poczatek RB, Dillard S, Weiss H, Brown D, Srivastava S, Grizzle WE. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 1997;74:346-58. [DOI: 10.1002/(sici)1097-0215(19970620)74:3<346::aid-ijc19>3.0.co;2-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
81 Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 1995;71:1003-7. [PMID: 7734290 DOI: 10.1038/bjc.1995.193] [Cited by in Crossref: 130] [Cited by in F6Publishing: 117] [Article Influence: 5.0] [Reference Citation Analysis]
82 Coupland SE, Bechrakis N, Schüler A, Anagnostopoulos I, Hummel M, Bornfeld N, Stein H. Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma. Br J Ophthalmol 1998;82:961-70. [PMID: 9828785 DOI: 10.1136/bjo.82.8.961] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 2.0] [Reference Citation Analysis]
83 Siziopikou KP, Schnitt SJ. MIB‐1 Proliferation Index in Ductal Carcinoma In Situ of the Breast: Relationship to the Expression of the Apoptosis‐Regulating Proteins bcl‐2 and p53. The Breast Journal 2008;6:400-6. [DOI: 10.1046/j.1524-4741.2000.99088.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
84 Berghella AM, Pellegrini P, Contasta I, Del Beato T, Adorno D. Bcl-2 and drugs used in the treatment of cancer: new strategies of biotherapy which should not be underestimated. Cancer Biother Radiopharm 1998;13:225-37. [PMID: 10850359 DOI: 10.1089/cbr.1998.13.225] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
85 Dagher E, Abadie J, Loussouarn D, Fanuel D, Campone M, Nguyen F. Bcl-2 expression and prognostic significance in feline invasive mammary carcinomas: a retrospective observational study. BMC Vet Res 2019;15:25. [PMID: 30630524 DOI: 10.1186/s12917-018-1772-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
86 Mattar A, Logullo AF, Facina G, Nonogaki S, Soares FA, Gebrim LH. Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial. J Cancer Res Clin Oncol 2011;137:897-905. [PMID: 20886231 DOI: 10.1007/s00432-010-0950-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
87 Cheng N, Janumyan YM, Didion L, Van Hofwegen C, Yang E, Knudson CM. Bcl-2 inhibition of T-cell proliferation is related to prolonged T-cell survival. Oncogene 2004;23:3770-80. [DOI: 10.1038/sj.onc.1207478] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
88 Pich A, Margaria E, Chiusa L. Oncogenes and Male Breast Carcinoma: c-erbB-2 and p53 Coexpression Predicts a Poor Survival. JCO 2000;18:2948-56. [DOI: 10.1200/jco.2000.18.16.2948] [Cited by in Crossref: 55] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
89 Collecchi P, Giannessi PG, Baldini E, Naccarato AG, Passoni A, Bevilacqua G, Conte PF. Effects of Primary Chemotherapy on Biological Parameters of Locally Advanced Breast Cancer. Ann NY Acad Sci 1996;784:419-26. [DOI: 10.1111/j.1749-6632.1996.tb16256.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
90 Reed JC, Miyashita T, Takayama S, Wang HG, Sato T, Krajewski S, Aimé-Sempé C, Bodrug S, Kitada S, Hanada M. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996;60:23-32. [PMID: 8825412 DOI: 10.1002/(SICI)1097-4644(19960101)60:1%3C23::AID-JCB5%3E3.0.CO;2-5] [Cited by in F6Publishing: 96] [Reference Citation Analysis]
91 Ferrières G, Cuny M, Simony-lafontaine J, Jacquemier J, Rouleau C, Guilleux F, Grenier J, Rouanet P, Pujol H, Jeanteur P, Escot C. Variation of bcl-2 expression in breast ducts and lobules in relation to plasma progesterone levels: overexpression and absence of variation in fibroadenomas. J Pathol 1997;183:204-11. [DOI: 10.1002/(sici)1096-9896(199710)183:2<204::aid-path921>3.0.co;2-m] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
92 Tolcher AW. Regulators of apoptosis as anticancer targets. Hematol Oncol Clin North Am 2002;16:1255-67. [PMID: 12512391 DOI: 10.1016/s0889-8588(02)00046-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 Subhawong AP, Nassar H, Halushka MK, Illei PB, Vang R, Argani P. Heterogeneity of Bcl-2 expression in metastatic breast carcinoma. Mod Pathol. 2010;23:1089-1096. [PMID: 20495533 DOI: 10.1038/modpathol.2010.93] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
94 Kong G, Yong Shin K, Ha Oh Y, Jin Lee J, Young Park H, Nam Woo Y, Dal Lee J. Bcl-2 and p53 Expressions in Invasive Bladder Cancers. Acta Oncologica 2009;37:715-20. [DOI: 10.1080/028418698430098] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
95 Ishida H, Irie K, Itoh T, Furukawa T, Tokunaga O. The prognostic significance of p53 andbcl-2 expression in lung adenocarcinoma and its correlation with ki-67 growth fraction. Cancer 1997;80:1034-45. [DOI: 10.1002/(sici)1097-0142(19970915)80:6<1034::aid-cncr5>3.0.co;2-9] [Cited by in Crossref: 72] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
96 L� MG, Mathieu M, Douc-rasy S, Le Bihan M, Adb El All H, Spielmann M, Riou G. c-myc, p53 andbcl-2, apoptosis-related genes in infiltrating breast carcinomas: Evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. Int J Cancer 1999;84:562-7. [DOI: 10.1002/(sici)1097-0215(19991222)84:6<562::aid-ijc4>3.0.co;2-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
97 Zhang J, Lahti JM, Bruce A, He L, Parihar K, Fan C, Grenet J, Liu L, Kidd VJ, Cormier S, Tang D. Identification of an ataxia telangiectasia-mutated protein mediated surveillance system to regulate Bcl-2 overexpression. Oncogene 2006;25:5601-11. [PMID: 16636671 DOI: 10.1038/sj.onc.1209565] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
98 Bodner K, Bodner-Adler B, Czerwenka K, Hudelist G, Kimberger O, Leodolter S, Mayerhofer K. Bcl-2 expression in a primary leiomyosarcoma of the ovary: a case report. Wien Klin Wochenschr 2003;115:191-5. [PMID: 12741081 DOI: 10.1007/BF03040309] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
99 Coppola D, Catalano E, Nicosia SV. Significance of p53 and Bcl-2 Protein Expression in Human Breast Ductal Carcinoma: This regular feature presents special issues in oncologic pathology. Cancer Control 1999;6:181-7. [DOI: 10.1177/107327489900600211] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
100 Paradiso A, Simone G, Lena MD, Leone B, Vallejo C, Lacava J, Dellapasqua S, Daidone MG, Costa A. Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. Br J Cancer. 2001;84:651-658. [PMID: 11237386 DOI: 10.1054/bjoc.2000.1658] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.1] [Reference Citation Analysis]
101 Wilson GD, Saunders M, Dische S, Richman P, Daley F, Bentzen SM. bcl-2 expression in head and neck cancer: an enigmatic prognostic marker. International Journal of Radiation Oncology*Biology*Physics 2001;49:435-41. [DOI: 10.1016/s0360-3016(00)01498-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
102 Daidone MG, Costa A, Silvestrini R. Cell proliferation markers in human solid tumors: Assessing their impact in clinical oncology. Cytometry: Part B. Elsevier; 2001. pp. 359-84. [DOI: 10.1016/s0091-679x(01)64022-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
103 Kim HE, Han SJ, Kasza T, Han R, Choi H, Palmer KC, Kim HC. Platelet-derived growth factor (PDGF)-signaling mediates radiation-induced apoptosis in human prostate cancer cells with loss of p53 function. International Journal of Radiation Oncology*Biology*Physics 1997;39:731-6. [DOI: 10.1016/s0360-3016(97)00358-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
104 Shangary S, Johnson DE. Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia 2003;17:1470-81. [DOI: 10.1038/sj.leu.2403029] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 2.9] [Reference Citation Analysis]
105 Grizzle WE. Biomarkers--the new frontier in the pathology of invasive and preinvasive neoplasias. Biotech Histochem 1997;72:59-61. [PMID: 9152518 DOI: 10.3109/10520299709082214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
106 Hao J, Gu Q, Liu B, Li J, Chen X, Ji Y, Zhu Z, Lin Y. Inhibition of the proliferation of human gastric cancer cells SGC-7901 in vitro and in vivo using Bcl-2 siRNA: . Chinese Medical Journal 2007;120:2105-11. [DOI: 10.1097/00029330-200712010-00008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
107 Arun B, Kilic G, Yen C, Foster B, Yardley D, Gaynor R, Ashfaq R. Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes. Cancer 2003;98:2554-9. [PMID: 14669273 DOI: 10.1002/cncr.11853] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
108 Zoeller JJ, Press MF, Selfors LM, Dering J, Slamon DJ, Hurvitz SA, Brugge JS. Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy. PLoS One 2021;16:e0251163. [PMID: 33951110 DOI: 10.1371/journal.pone.0251163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Bozzetti C, Nizzoli R, Naldi N, Guazzi A, Camisa R, Bella MA, Cocconi G. Bcl-2 expression on fine-needle aspirates from primary breast carcinoma: Correlation with other biologic factors. Cancer 1999;87:224-30. [DOI: 10.1002/(sici)1097-0142(19990825)87:4<224::aid-cncr10>3.0.co;2-5] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
110 Merino D, Best SA, Asselin-Labat ML, Vaillant F, Pal B, Dickins RA, Anderson RL, Strasser A, Bouillet P, Lindeman GJ, Visvader JE. Pro-apoptotic Bim suppresses breast tumor cell metastasis and is a target gene of SNAI2. Oncogene 2015;34:3926-34. [PMID: 25263453 DOI: 10.1038/onc.2014.313] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
111 Burke PA, DeNardo SJ, Miers LA, Kukis DL, DeNardo GL. Combined modality radioimmunotherapy. Promise and peril. Cancer 2002;94:1320-31. [PMID: 11877763 DOI: 10.1002/cncr.10303] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
112 Shishido SN, Nguyen TA. Induction of Apoptosis by PQ1, a Gap Junction Enhancer that Upregulates Connexin 43 and Activates the MAPK Signaling Pathway in Mammary Carcinoma Cells. Int J Mol Sci 2016;17:E178. [PMID: 26840298 DOI: 10.3390/ijms17020178] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
113 Jin Y, Kayser S, Kemp BL, Ordonez NG, Tucker SL, Clayman GL, Goepfert H, Luna MA, Batsakis JG, El-naggar AK. The prognostic significance of the biomarkers p21WAF1/CIP1, p53, andbcl-2 in laryngeal squamous cell carcinoma. Cancer 1998;82:2159-65. [DOI: 10.1002/(sici)1097-0142(19980601)82:11<2159::aid-cncr10>3.0.co;2-t] [Cited by in Crossref: 47] [Article Influence: 2.0] [Reference Citation Analysis]
114 Kim HH, Park CS. LIPOTROPES REGULATE BCL-2 GENE EXPRESSION IN THE HUMAN BREAST CANCER CELL LINE, MCF-7. In Vitro Cell Dev Biol Anim 2002;38:205. [DOI: 10.1290/1071-2690(2002)038<0205:lrbgei>2.0.co;2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
115 Merino D, Lok SW, Visvader JE, Lindeman GJ. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. Oncogene 2016;35:1877-87. [PMID: 26257067 DOI: 10.1038/onc.2015.287] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 11.2] [Reference Citation Analysis]
116 Mommers ECM, Leonhart AM, Falix F, Michalides R, Meijer CJLM, Baak JPA, Diest PJV. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. J Pathol 2001;194:327-33. [DOI: 10.1002/path.910] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
117 Liang XH, Mungal S, Ayscue A, Meissner JD, Wodnicki P, Hockenbery D, Lockett S, Herman B. Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. J Cell Biochem 1995;57:509-21. [DOI: 10.1002/jcb.240570316] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 1.9] [Reference Citation Analysis]
118 Sumantran VN, Lee DS, Baker VV, Murray S, Strawderman M, Wicha MS. A Bcl-xS Adenovirus Demonstrates Therapeutic Efficacy in an Ascites Model of Human Breast Cancer. Journal of the Society for Gynecologic Investigation 2016;7:184-9. [DOI: 10.1177/107155760000700308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
119 Ellison DW, Steart PV, Gatter KC, Weller RO. Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl-2 and p53 proteins. Neuropathol Appl Neurobiol 1995;21:352-61. [DOI: 10.1111/j.1365-2990.1995.tb01070.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 51] [Article Influence: 1.5] [Reference Citation Analysis]
120 Daidone MG, Silvestrini R, Luisi A, Mastore M, Benini E, Veneroni S, Brambilla C, Ferrari L, Greco M, Andreola S, Veronesi U. Changes in biological markers after primary chemotherapy for breast cancers. Int J Cancer 1995;61:301-5. [DOI: 10.1002/ijc.2910610304] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.2] [Reference Citation Analysis]
121 Reed JC. BCL-2: Prevention of Apoptosis as a Mechanism of Drug Resistance. Hematology/Oncology Clinics of North America 1995;9:451-74. [DOI: 10.1016/s0889-8588(18)30104-7] [Cited by in Crossref: 203] [Article Influence: 7.8] [Reference Citation Analysis]
122 Ravaioli A, Bagli L, Zucchini A, Monti F. Prognosis and prediction of response in breast cancer: the current role of the main biological markers: Review. Cell Proliferation 1998;31:113-26. [DOI: 10.1111/j.1365-2184.1998.tb01190.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
123 Johnston SR, MacLennan KA, Sacks NP, Salter J, Smith IE, Dowsett M. Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer 1994;30A:1663-9. [PMID: 7833141 DOI: 10.1016/0959-8049(94)00327-2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 1.8] [Reference Citation Analysis]
124 Kim JH, Lee H, Shin EA, Kim DH, Choi JB, Kim SH. Implications of Bcl-2 and its interplay with other molecules and signaling pathways in prostate cancer progression. Expert Opin Ther Targets 2017;21:911-20. [PMID: 28816549 DOI: 10.1080/14728222.2017.1369044] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
125 Lipponen P, Pietiläinen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrjänen K. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 1995;177:49-55. [PMID: 7472779 DOI: 10.1002/path.1711770109] [Cited by in Crossref: 93] [Cited by in F6Publishing: 92] [Article Influence: 3.6] [Reference Citation Analysis]
126 Guimarães Tiezzi D, Moreira De Andrade J, José Cândido Dos Reis F, Ricardo Cosiski Marana H, Ribeiro-silva A, Guimarães Tiezzi M, Plácido Pereira A. Apoptosis induced by neoadjuvant chemotherapy in breast cancer. Pathology 2006;38:21-7. [DOI: 10.1080/00313020500465315] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
127 Zhang G, Tsuda H, Adachi I, Fukutomi T, Yamamoto H, Hirohashi S. Prognostic Indicators for Breast Cancer Patients With One to Three Regional Lymph Node Metastases, With Special Reference to Alterations in Expression Levels of bcl-2, p53 and c-erbB-2 Proteins. Japanese Journal of Clinical Oncology 1997;27:371-7. [DOI: 10.1093/jjco/27.6.371] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
128 Henriksen R, Wilander E, Oberg K. Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer 1995;72:1324-9. [PMID: 7577491 DOI: 10.1038/bjc.1995.509] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 2.9] [Reference Citation Analysis]
129 Vagunda V, Šmardová J, Vagundová M, Jandáková E, Žaloudík J, Koukalová H. Correlations of Breast Carcinoma Biomarkers and p53 Tested by FASAY and Immunohistochemistry. Pathology - Research and Practice 2003;199:795-801. [DOI: 10.1078/0344-0338-00498] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
130 Kang M, Mitomi H, Sada M, Tokumitsu Y, Takahashi Y, Igarashi M, Katsumata T, Okayasu I. Ki-67, p53, and Bcl-2 expression of serrated adenomas of the colon. Am J Surg Pathol. 1997;21:417-423. [PMID: 9130988 DOI: 10.1097/00000478-199704000-00007] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 2.0] [Reference Citation Analysis]
131 Lopes-Costa PV, dos Santos AR, dos Santos LG, da Silva BB. Evaluation of Ki-67 and Bcl-2 antigen expression in breast carcinomas of women treated with raloxifene. Cell Prolif 2010;43:124-9. [PMID: 20447057 DOI: 10.1111/j.1365-2184.2009.00664.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
132 Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, Yamaguchi H, Xie X, Woodward WA, Yu D, Hortobagyi GN, Hung MC. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell 2011;20:341-56. [PMID: 21907925 DOI: 10.1016/j.ccr.2011.07.017] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 6.0] [Reference Citation Analysis]
133 Liu FS, Jan YJ, Lai CR, Twu NF, Lu CH, Hung MJ, Hsieh YT, Chiou LC. Expression analysis of apoptosis-related markers TP53, BCL-2, BAX and c-MYC in female genital tract sarcomas. J Chin Med Assoc 2008;71:628-34. [PMID: 19114327 DOI: 10.1016/S1726-4901(09)70005-X] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
134 Elzagheid A, Kuopio T, Pyrhönen S, Collan Y. Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future? Diagn Pathol 2006;1:41. [PMID: 17092354 DOI: 10.1186/1746-1596-1-41] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
135 Luke JJ, Van De Wetering CI, Knudson CM. Lymphoma development in Bax transgenic mice is inhibited by Bcl-2 and associated with chromosomal instability. Cell Death Differ 2003;10:740-8. [PMID: 12761582 DOI: 10.1038/sj.cdd.4401233] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
136 Callagy GM, Webber MJ, Pharoah PD, Caldas C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 2008;8:153. [PMID: 18510726 DOI: 10.1186/1471-2407-8-153] [Cited by in Crossref: 118] [Cited by in F6Publishing: 112] [Article Influence: 9.1] [Reference Citation Analysis]
137 Bánkfalvi A, Tory K, Kemper M, Breukelmann D, Cubick C, Poremba C, Füzesi L, Lellè RJ, Böcker W. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma. Pathol Res Pract 2000;196:489-501. [PMID: 10926327 DOI: 10.1016/S0344-0338(00)80051-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
138 Nio Y, Iguchi C, Yamasawa K, Sasaki S, Takamura M, Toga T, Dong M, Itakura M, Tamura K. Apoptosis and expression of Bcl-2 and Bax proteins in invasive ductal carcinoma of the pancreas. Pancreas 2001;22:230-9. [PMID: 11291923 DOI: 10.1097/00006676-200104000-00002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
139 Bodey B, Bodey B, Siegel SE, Kaiser HE. Immunocytochemical detection of leukocyte-associated and apoptosis-related antigen expression in childhood brain tumors. Crit Rev Oncol Hematol. 2001;39:3-16. [PMID: 11418297 DOI: 10.1016/s1040-8428(01)00119-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
140 Escórcio-Dourado CS, Martins LM, Simplício-Revoredo CM, Sampaio FA, Tavares CB, da Silva-Sampaio JP, Borges US, Alves-Ribeiro FA, Lopes-Costa PV, Lima-Dourado JC, da Silva BB. Bcl-2 antigen expression in luminal A and triple-negative breast cancer. Med Oncol 2017;34:161. [PMID: 28801774 DOI: 10.1007/s12032-017-1022-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
141 Daidone MG, Coradini D, Martelli G, Veneroni S. Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Critical Reviews in Oncology/Hematology 2003;45:313-25. [DOI: 10.1016/s1040-8428(02)00144-0] [Cited by in Crossref: 99] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
142 Treré D, Montanaro L, Ceccarelli C, Barbieri S, Cavrini G, Santini D, Taffurelli M, Derenzini M. Prognostic relevance of a novel semiquantitative classification of Bcl2 immunohistochemical expression in human infiltrating ductal carcinomas of the breast. Ann Oncol 2007;18:1004-14. [PMID: 17372162 DOI: 10.1093/annonc/mdm074] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
143 Amadori D, Silvestrini R. Prognostic and predictive value of thymidine labelling index in breast cancer. Breast Cancer Res Treat 1998;51:267-81. [DOI: 10.1023/a:1006140629766] [Cited by in Crossref: 27] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
144 Takayama T, Nagao M, Sawada H, Yamada Y, Emoto K, Fujimoto H, Ueno M, Hirao S, Nakajima Y. Bcl-X expression in esophageal squamous cell carcinoma: association with tumor progression and prognosis. J Surg Oncol. 2001;78:116-123. [PMID: 11579389 DOI: 10.1002/jso.1130] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
145 Darvishian F, Konno F, Qian M, Cangiarella J. Breast carcinoma with tubulopapillary features: a variant of papillary carcinoma with a stronger correlation with predictors of adverse prognosis. Int J Surg Pathol 2014;22:47-54. [PMID: 24008438 DOI: 10.1177/1066896913501381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
146 Bold RJ, Hess KR, Pearson AS, Grau AM, Sinicrope FA, Jennings M, McConkey DJ, Bucana CD, Cleary KR, Hallin PA, Chiao PJ, Abbruzzese JL, Evans DB. Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg 1999;3:263-77. [PMID: 10481119 DOI: 10.1016/s1091-255x(99)80068-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
147 Zaha DC. Significance of immunohistochemistry in breast cancer. World J Clin Oncol 2014; 5(3): 382-392 [PMID: 25114853 DOI: 10.5306/wjco.v5.i3.382] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 67] [Article Influence: 12.1] [Reference Citation Analysis]
148 Steck KD, Mcdonnell TJ, El-naggar AK. Flow cytometric analysis of apoptosis and BCL-2 in human solid neoplasms. Cytometry 1995;20:154-61. [DOI: 10.1002/cyto.990200208] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
149 Jing X, Kakudo K, Murakami M, Nakamura Y, Nakamura M, Yokoi T, Yang Q, Oura S, Sakurai T. Intraductal spread of invasive breast carcinoma has a positive correlation with c-erb B-2 overexpression and vascular invasion. Cancer 1999;86:439-48. [DOI: 10.1002/(sici)1097-0142(19990801)86:3<439::aid-cncr12>3.0.co;2-u] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
150 Leighton X, Eidelman O, Jozwik C, Pollard HB, Srivastava M. ANXA7-GTPase as Tumor Suppressor: Mechanisms and Therapeutic Opportunities. Methods Mol Biol 2017;1513:23-35. [PMID: 27807828 DOI: 10.1007/978-1-4939-6539-7_3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
151 Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood. 2008;111:3322-3330. [PMID: 18362212 DOI: 10.1182/blood-2007-09-078162] [Cited by in Crossref: 220] [Cited by in F6Publishing: 202] [Article Influence: 16.9] [Reference Citation Analysis]
152 Mcdonnel TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ. Expression of BCL-2 Oncoprotein and P53 Protein Accumulation in Bone Marrow Metastases of Androgen Independent Prostate Cancer. Journal of Urology 1997;157:569-74. [DOI: 10.1016/s0022-5347(01)65204-2] [Cited by in Crossref: 88] [Article Influence: 3.7] [Reference Citation Analysis]
153 Freneaux P, Stoppa-Lyonnet D, Mouret E, Kambouchner M, Nicolas A, Zafrani B, Vincent-Salomon A, Fourquet A, Magdelenat H, Sastre-Garau X. Low expression of bcl-2 in Brca1-associated breast cancers. Br J Cancer 2000;83:1318-22. [PMID: 11044356 DOI: 10.1054/bjoc.2000.1438] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
154 Rehman S, Crow J, Revell PA. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers. Pathol Oncol Res 2000;6:256-63. [DOI: 10.1007/bf03187328] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
155 Kannan TP, Ali AQ, Abdullah SF, Ahmad A. Evaluation of Tualang honey as a supplement to fetal bovine serum in cell culture. Food and Chemical Toxicology 2009;47:1696-702. [DOI: 10.1016/j.fct.2009.04.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
156 Reed JC. Bcl-2 Family Proteins. In: Hickman JA, Dive C, editors. Apoptosis and Cancer Chemotherapy. Totowa: Humana Press; 1999. pp. 99-116. [DOI: 10.1007/978-1-59259-720-8_7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
157 Cho J, Kim WH. Altered topographic expression of p21WAF1/CIP1/SDI1, bcl2 and p53 during gastric carcinogenesis. Pathology - Research and Practice 1998;194:309-17. [DOI: 10.1016/s0344-0338(98)80054-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
158 Grossi F, Loprevite M, Chiaramondia M, Ceppa P, Pera C, Ratto GB, Serrano J, Ferrara GB, Costa R, Boni L. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. Eur J Cancer. 2003;39:1242-1250. [PMID: 12763212 DOI: 10.1016/S0959-8049(03)00232-6] [Cited by in Crossref: 58] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
159 Zoeller JJ, Bronson RT, Selfors LM, Mills GB, Brugge JS. Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo. NPJ Breast Cancer 2017;3:18. [PMID: 28649658 DOI: 10.1038/s41523-017-0020-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
160 Czuczman MS, Grillo-López AJ, McLaughlin P, White CA, Saleh M, Gordon L, LoBuglio AF, Rosenberg J, Alkuzweny B, Maloney D. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol 2001;12:109-14. [PMID: 11249036 DOI: 10.1023/a:1008395214584] [Cited by in Crossref: 46] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
161 Polverini PJ, Nör JE. Apoptosis and predisposition to oral cancer. Crit Rev Oral Biol Med 1999;10:139-52. [PMID: 10759418 DOI: 10.1177/10454411990100020201] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
162 Park SH, Kim H, Song BJ. Down regulation of bcl2 expression in invasive ductal carcinomas is both estrogen- and progesterone-receptor dependent and associated with poor prognostic factors. Pathol Oncol Res 2002;8:26-30. [PMID: 11994759 DOI: 10.1007/BF03033697] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
163 Tsutsui S, Yasuda K, Suzuki K, Takeuchi H, Nishizaki T, Higashi H, Era S. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer. BMC Cancer 2006;6:187. [PMID: 16839413 DOI: 10.1186/1471-2407-6-187] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
164 Kymionis G, Dimitrakakis C, Konstadoulakis M, Arzimanoglou I, Leandros E, Chalkiadakis G, Keramopoulos A, Michalas S. Can Expression of Apoptosis Genes, bcl-2 and bax, Predict Survival and Responsiveness to Chemotherapy in Node-Negative Breast Cancer Patients? Journal of Surgical Research 2001;99:161-8. [DOI: 10.1006/jsre.2001.6084] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
165 Sierra A, Castellsagué X, Escobedo A, Lloveras B, García-ramirez M, Moreno A, Fabra A. Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: A pathway to metastatic progression in human breast cancer. Int J Cancer 2000;89:142-7. [DOI: 10.1002/(sici)1097-0215(20000320)89:2<142::aid-ijc7>3.0.co;2-b] [Cited by in Crossref: 23] [Article Influence: 1.1] [Reference Citation Analysis]
166 Volpi A, Nanni O, Vecci AM, Naldi S, Bernardi L, Marri L, Fedeli SL, Serra P, Amadori D. Feasibility of a Cell Kinetic-Based Adjuvant Chemotherapy Trial in Axillary Node-Negative Breast Cancer. Tumori 2000;86:142-8. [DOI: 10.1177/030089160008600207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
167 Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Mayerhofer K. Bcl-2 expression and other clinicopathologic parameters in uterine leiomyosarcoma. Wien Klin Wochenschr 2004;116:135-9. [PMID: 15038405 DOI: 10.1007/BF03040751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
168 Ferrero JM, Ramaioli A, Formento JL, Francoual M, Etienne MC, Peyrottes I, Ettore F, Leblanc-Talent P, Namer M, Milano G. p53 determination alongside classical prognostic factors in node-negative breast cancer: an evaluation at more than 10-year follow-up. Ann Oncol. 2000;11:393-397. [PMID: 10847456 DOI: 10.1023/a:1008359722254] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
169 Vargas-Roig LM, Cuello-Carrión FD, Fernández-Escobar N, Daguerre P, Leuzzi M, Ibarra J, Gago FE, Nadin SB, Ciocca DR. Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy. Mol Oncol 2008;2:102-11. [PMID: 19383332 DOI: 10.1016/j.molonc.2008.01.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
170 Gallo O, Chiarelli I, Boddi V, Bocciolini C, Bruschini L, Porfirio B. Cumulative prognostic value ofp53 mutations and bcl-2 protein expression in head-and-neck cancer treated by radiotherapy. Int J Cancer 1999;84:573-9. [DOI: 10.1002/(sici)1097-0215(19991222)84:6<573::aid-ijc6>3.0.co;2-r] [Cited by in Crossref: 48] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
171 Friedman M, Lim JW, Manders E, Schaffner AD, Kirshenbaum GL, Tanyeri HM, Caldarelli DD, Coon JS. Prognostic significance of Bcl-2 and p53 expression in advanced laryngeal squamous cell carcinoma. Head Neck 2001;23:280-5. [PMID: 11400228 DOI: 10.1002/hed.1031] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
172 Veronese ML, Bullrich F, Croce CM. Oncogenes and Mammary Carcinogenesis. In: Manni A, editor. Endocrinology of Breast Cancer. Totowa: Humana Press; 1999. pp. 93-108. [DOI: 10.1007/978-1-59259-699-7_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
173 Nicholson AD, Guo X, Sullivan CA, Cha CH. Automated Quantitative Analysis of Tissue Microarray of 443 Patients with Colorectal Adenocarcinoma: Low Expression of Bcl-2 Predicts Poor Survival. Journal of the American College of Surgeons 2014;219:977-87. [DOI: 10.1016/j.jamcollsurg.2014.07.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
174 Schiller A, Clark W, Cotsonis G, Lawson D, Derose P, Cohen C. Image cytometric bcl-2:bax and bcl-2:bcl-x ratios in invasive breast carcinoma: Correlation with prognosis. Cytometry 2002;50:203-9. [DOI: 10.1002/cyto.10091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
175 Muller-höcker J, Obernitz N, Johannes A, Lührs U. P53 gene product and egf-receptor are highly expressed in placental site trophoblastic tumor. Human Pathology 1997;28:1302-6. [DOI: 10.1016/s0046-8177(97)90206-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
176 Haffty BG, Glazer PM. Molecular markers in clinical radiation oncology. Oncogene 2003;22:5915-25. [DOI: 10.1038/sj.onc.1206704] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
177 van Slooten HJ, Clahsen PC, van Dierendonck JH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van de Velde CJ, van de Vijver MJ. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer 1996;74:78-85. [PMID: 8679463 DOI: 10.1038/bjc.1996.319] [Cited by in Crossref: 81] [Cited by in F6Publishing: 79] [Article Influence: 3.2] [Reference Citation Analysis]
178 Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nisticò C, Fabi A, Buglioni S, Natali PG, Mottolese M. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res 2008;10:R74. [PMID: 18771580 DOI: 10.1186/bcr2139] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 5.2] [Reference Citation Analysis]
179 Glinsky GV. Apoptosis in metastatic cancer cells. Crit Rev Oncol Hematol. 1997;25:175-186. [PMID: 9177940 DOI: 10.1016/s1040-8428(97)00234-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
180 Chen S, Zhang J, Li X, Luo X, Fang J, Chen H. The expression of prolyl hydroxylase domain enzymes are up-regulated and negatively correlated with Bcl-2 in non-small cell lung cancer. Mol Cell Biochem 2011;358:257-63. [PMID: 21748337 DOI: 10.1007/s11010-011-0976-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
181 Reed JC. Bcl-2 Family Proteins: Strategies for Overcoming Chemoresistance in Cancer. Apoptosls - Pharmacological Implications and Therapeutic Opportunities. Elsevier; 1997. pp. 501-32. [DOI: 10.1016/s1054-3589(08)61070-4] [Cited by in Crossref: 75] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
182 Tjalma WA, Weyler JJ, Bogers JJ, Pollefliet C, Baay M, Goovaerts GC, Vermorken JB, van Dam PA, van Marck EA, Buytaert PM. The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology 2001;97:223-30. [DOI: 10.1016/s0301-2115(00)00541-8] [Cited by in Crossref: 51] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
183 Ali AQ, Kannan TP, Ahmad A, Samsudin AR. In vitro genotoxicity tests for polyhydroxybutyrate – A synthetic biomaterial. Toxicology in Vitro 2008;22:57-67. [DOI: 10.1016/j.tiv.2007.08.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
184 Nuñez G, Clarke MF. The Bcl-2 family of proteins: regulators of cell death and survival. Trends in Cell Biology 1994;4:399-403. [DOI: 10.1016/0962-8924(94)90053-1] [Cited by in Crossref: 143] [Cited by in F6Publishing: 151] [Article Influence: 5.3] [Reference Citation Analysis]
185 Akın A, Alehan D, Aykan HH, Özkutlu S, Özer S, Karagöz T. Serum Bcl-2 values in children with pulmonary hypertension. Pediatr Cardiol 2015;36:579-83. [PMID: 25381623 DOI: 10.1007/s00246-014-1052-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
186 Stattin P, Damber J-, Karlberg L, Nordgren H, Bergh A. Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival. Urol Res 1996;24:257-64. [DOI: 10.1007/bf00304774] [Cited by in Crossref: 30] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
187 Neri A, Marrelli D, Roviello F, DeMarco G, Mariani F, DeStefano A, Megha T, Caruso S, Corso G, Cioppa T, Pinto E. Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer. Breast Cancer Res Treat 2006;99:77-83. [PMID: 16541314 DOI: 10.1007/s10549-006-9183-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
188 Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 1995;72:354-60. [PMID: 7640218 DOI: 10.1038/bjc.1995.338] [Cited by in Crossref: 122] [Cited by in F6Publishing: 115] [Article Influence: 4.7] [Reference Citation Analysis]
189 Hwang KT, Woo JW, Shin HC, Kim HS, Ahn SK, Moon HG, Han W, Park IA, Noh DY. Prognostic influence of BCL2 expression in breast cancer. Int J Cancer 2012;131:E1109-19. [PMID: 22418857 DOI: 10.1002/ijc.27539] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
190 Frassoldati A, Adami F, Banzi C, Criscuolo M, Piccinini L, Silingardi V. Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res Treat 1997;44:185-92. [DOI: 10.1023/a:1005875002458] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
191 Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002;235:10-26. [PMID: 11753038 DOI: 10.1097/00000658-200201000-00003] [Cited by in Crossref: 170] [Cited by in F6Publishing: 150] [Article Influence: 8.9] [Reference Citation Analysis]
192 Caffrey E, Ingoldsby H, Wall D, Webber M, Dinneen K, Murillo LS, Inderhaug C, Newell J, Gupta S, Callagy G. Prognostic significance of deregulated dicer expression in breast cancer. PLoS One 2013;8:e83724. [PMID: 24386264 DOI: 10.1371/journal.pone.0083724] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
193 Tjalma W, Weyler J, Goovaerts G, De Pooter C, Van Marck E, van Dam P. Prognostic value of bcl-2 expression in patients with operable carcinoma of the uterine cervix. J Clin Pathol 1997;50:33-6. [PMID: 9059353 DOI: 10.1136/jcp.50.1.33] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.2] [Reference Citation Analysis]
194 Nigam S, Kumar GS, Sutherland M, Schewe T, Ikawa H, Yamasaki Y, Ueda N, Yamamoto S. Metabolic suppression of platelet-type 12-lipoxygenase in human uterine cervix with invasive carcinoma. Int J Cancer 1999;82:827-31. [DOI: 10.1002/(sici)1097-0215(19990909)82:6<827::aid-ijc10>3.0.co;2-q] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
195 Ding D, Ping W, Haiyan J, Coling D, Salvi R. Gene expression in cisplatin ototoxicity and protection with p53 inhibitor. Journal of Otology 2009;4:61-70. [DOI: 10.1016/s1672-2930(09)50016-5] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
196 Elkhuizen PH, Voogd AC, van den Broek LC, Tan IT, van Houwelingen HC, Leer JH, van de Vijver MJ. Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. International Journal of Radiation Oncology*Biology*Physics 1999;45:73-83. [DOI: 10.1016/s0360-3016(99)00158-3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
197 Reed JC, Miyashita T, Krajewski S, Takayama S, Aime-Sempe C, Kitada S, Sato T, Wang HG, Harigai M, Hanada M, Krajewska M, Kochel K, Millan J, Kobayashi H. Bcl-2 family proteins and the regulation of programmed cell death in leukemia and lymphoma. Cancer Treat Res 1996;84:31-72. [PMID: 8724625 DOI: 10.1007/978-1-4613-1261-1_3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.1] [Reference Citation Analysis]
198 Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox S, Bonzanini M, Girlando S, Morelli L, Eccher C, Pezzella F, Doglioni C, Dalla Palma P, Harris A. Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol 1996;27:1149-55. [PMID: 8912823 DOI: 10.1016/s0046-8177(96)90307-x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
199 Ali HR, Dawson S, Blows FM, Provenzano E, Leung S, Nielsen T, Pharoah PD, Caldas C. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer: A Ki67/BCL2 index is highly prognostic in ER-positive breast cancer. J Pathol 2012;226:97-107. [DOI: 10.1002/path.2976] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 5.4] [Reference Citation Analysis]
200 Campbell KJ, Dhayade S, Ferrari N, Sims AH, Johnson E, Mason SM, Dickson A, Ryan KM, Kalna G, Edwards J, Tait SWG, Blyth K. MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death Dis 2018;9:19. [PMID: 29339815 DOI: 10.1038/s41419-017-0035-2] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 22.7] [Reference Citation Analysis]
201 Tzouvala M, Lazaris AC, Papatheodoridis GV, Kouvidou C, Papathomas TG, Kavantzas N, Elemenoglou I, Karamanolis DG, Agapitos E. Potential role of apoptosis and apoptotic regulatory proteins in colorectal neoplasia: correlations with clinico-pathological parameters and survival. Dig Dis Sci 2008;53:451-60. [PMID: 17562177 DOI: 10.1007/s10620-007-9857-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
202 Malamou-Mitsi V, Gogas H, Dafni U, Bourli A, Fillipidis T, Sotiropoulou M, Vlachodimitropoulos D, Papadopoulos S, Tzaida O, Kafiri G, Kyriakou V, Markaki S, Papaspyrou I, Karagianni E, Pavlakis K, Toliou T, Scopa C, Papakostas P, Bafaloukos D, Christodoulou C, Fountzilas G. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann Oncol 2006;17:1504-11. [PMID: 16968874 DOI: 10.1093/annonc/mdl147] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
203 Campbell KJ, Tait SWG. Targeting BCL-2 regulated apoptosis in cancer. Open Biol 2018;8:180002. [PMID: 29769323 DOI: 10.1098/rsob.180002] [Cited by in Crossref: 173] [Cited by in F6Publishing: 158] [Article Influence: 86.5] [Reference Citation Analysis]
204 Sundblad AS, Pellicer E, Ricci L. Carcinoembryonic antigen expression in stages I and II breast cancer: Its relationship with clinicopathologic factors. Human Pathology 1996;27:297-301. [DOI: 10.1016/s0046-8177(96)90072-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
205 Tsuda H, Sakamaki C, Tsugane S, Fukutomi T, Hirohashi S. A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases. Breast Cancer Res Treat 1998;48:21-32. [DOI: 10.1023/a:1005977630830] [Cited by in Crossref: 32] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
206 Dijkema I, Struikmans H, Dullens H, Kal H, van der Tweel I, Battermann J. Influence of p53 and bcl-2 on proliferative activity and treatment outcome in head and neck cancer patients. Oral Oncology 2000;36:54-60. [DOI: 10.1016/s1368-8375(99)00051-2] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
207 Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999;17:2941-53. [PMID: 10561374 DOI: 10.1200/JCO.1999.17.9.2941] [Cited by in Crossref: 621] [Cited by in F6Publishing: 182] [Article Influence: 29.6] [Reference Citation Analysis]
208 Takano Y, Saegusa M, Ikenaga M, Okayasu I. Apoptosis and proliferative activity of non-Hodgkin's lymphomas: Comparison with expression of bcl-2, p53 and c-myc proteins. Pathology International 1997;47:90-4. [DOI: 10.1111/j.1440-1827.1997.tb03726.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
209 Nio Y, Dong M, Iguchi C, Yamasawa K, Toga T, Itakura M, Tamura K. Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy. J Surg Oncol 2001;76:188-96. [PMID: 11276023 DOI: 10.1002/jso.1033] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
210 Cunha KS, Caruso AC, Faria PA, Silva LED, Fonseca ECD, Geller M, Moura-neto RSD, Lopes VS. Evaluation of Bcl-2, Bcl-x and Cleaved Caspase-3 in Malignant Peripheral Nerve Sheath Tumors and Neurofibromas. An Acad Bras Ciênc 2013;85:1497-511. [DOI: 10.1590/0001-3765201320120026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
211 Eissa S, Seada LS. Quantitation of bcl-2 protein in bladder cancer tissue by enzyme immunoassay: comparison with Western blot and immunohistochemistry. Clinical Chemistry 1998;44:1423-9. [DOI: 10.1093/clinchem/44.7.1423] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
212 Homma A, Furuta Y, Oridate N, Nakano Y, Yagi K, Nagahashi T, Fukuda S, Inuyama Y. Correlation of clinicopathological parameters and biological markers related to apoptosis and proliferative activity with a clinical outcome in squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy. Auris Nasus Larynx 2001;28 Suppl:S87-94. [PMID: 11683351 DOI: 10.1016/s0385-8146(01)00067-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
213 Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S, López-berestein G, Andreeff M. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 2000;95:3929-38. [DOI: 10.1182/blood.v95.12.3929] [Cited by in Crossref: 72] [Article Influence: 3.4] [Reference Citation Analysis]
214 Ohshio G, Suwa H, Imamura T, Yamaki K, Tanaka T, Hashimoto Y, Imamura M. An immunohistochemical study of bcl-2 and p53 protein expression in pancreatic carcinomas. Scand J Gastroenterol 1998;33:535-9. [PMID: 9648995 DOI: 10.1080/00365529850172124] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
215 Gómez-Navarro J, Arafat W, Xiang J. Gene therapy for carcinoma of the breast: Pro-apoptotic gene therapy. Breast Cancer Res. 2000;2:32-44. [PMID: 11250691 DOI: 10.1186/bcr27] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
216 Sierra A, Lloveras B, Castellsagué X, Moreno L, García-Ramirez M, Fabra A. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer. 1995;60:54-60. [PMID: 7814152 DOI: 10.1002/ijc.2910600108] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 2.7] [Reference Citation Analysis]
217 Manne U, Weiss HL, Grizzle WE. Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas. Int J Cancer 2000;89:423-30. [DOI: 10.1002/1097-0215(20000920)89:5<423::aid-ijc5>3.0.co;2-t] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
218 Kuropkat C, Venkatesan T, Caldarelli D, Panje W, Hutchinson J, Preisler H, Coon J, Werner J. Abnormalities of molecular regulators of proliferation and apoptosis in carcinoma of the oral cavity and oropharynx. Auris Nasus Larynx 2002;29:165-74. [DOI: 10.1016/s0385-8146(01)00129-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
219 Ravaioli A, Bagli L, Zucchini A, Monti F. Prognosis and prediction of response in breast cancer: the current role of the main biological markers. Cell Prolif 1998;31:113-26. [PMID: 9853425 [PMID: 9853425 DOI: 10.1046/j.1365-2184.1998.t01-1-00114.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
220 Miturski R, Semczuk A, Tomaszewski J, Jakowicki J. bcl-2 protein expression in endometrial carcinoma: the lack of correlation with p53. Cancer Letters 1998;133:63-9. [DOI: 10.1016/s0304-3835(98)00193-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
221 Holmqvist P, Lundström M, Stål O, Arnesson L, Nordenskjöld B, Nordenskjöld K, Malmström A, Bång H, Källström A, Einarsson E, Norberg B, Adlouni W, Henning Å, Sundquist M, Tejler G; THE SOUTH-EAST SWEDEN BREAST CANCER GROUP. Apoptosis and Bcl-2 Expression in Relation to Age, Tumor Characteristics and Prognosis in Breast Cancer. Int J Biol Markers 1999;14:84-91. [DOI: 10.1177/172460089901400205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
222 Papadimitriou CS, Costopoulos JS, Christoforidou BP, Kotsianti AJ, Karkavelas GS, Hytiroglou PM, Koufogiannis DJ, Nenopoulou HE. Expression of Bcl-2 protein in human primary breast carcinomas and its correlation with multifocality, histopathological types and prognosis. Eur J Cancer. 1997;33:1275-1280. [PMID: 9301455 DOI: 10.1016/s0959-8049(97)00124-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
223 Seong MK, Lee JY, Byeon J, Sohn YJ, Seol H, Lee JK, Kim EK, Kim HA, Noh WC. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer. Breast Cancer Res Treat 2015;150:141-8. [PMID: 25682076 DOI: 10.1007/s10549-015-3305-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
224 Ma L, Ronai A, Riede UN, K??hler G. Expression of p53 and Bcl-2 in Squamous-Cell Carcinoma of the Head and Neck: An Immunohistochemical Study: . Applied Immunohistochemistry 1998;6:77-83. [DOI: 10.1097/00022744-199806000-00004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
225 Calastretti A, Rancati F, Ceriani M, Asnaghi L, Canti G, Nicolin A. Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect. European Journal of Cancer 2001;37:2121-8. [DOI: 10.1016/s0959-8049(01)00256-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
226 Bozovic-spasojevic I, Ameye L, Paesmans M, Larsimont D, Di Leo A, Dolci S, Piccart M, de Azambuja E, Loi S. Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. The Breast 2014;23:473-81. [DOI: 10.1016/j.breast.2014.03.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
227 Re GG, Hazen-martin DJ, Bahtimi RE, Brownlee NA, Willingham MC, Garvin AJ. Prognostic significance of Bcl-2 in Wilms' tumor and oncogenic potential of Bcl-XL in rare tumor cases. Int J Cancer 1999;84:192-200. [DOI: 10.1002/(sici)1097-0215(19990420)84:2<192::aid-ijc17>3.0.co;2-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
228 Hayes D, Paoletti C. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Breast Diseases: A Year Book Quarterly 2011;22:160-2. [DOI: 10.1016/j.breastdis.2011.03.048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
229 Facina G, Lopes-Costa PV, Dos Santos AR, De Vasconcelos-Valença RJ, Pinho-Sobral AL, Ferreira-Filho CP, Alencar AP, Gebrim LH, Da Silva BB. Immunohistochemical expression of E-cadherin in sclerosing adenosis, ductal carcinoma in situ and invasive ductal carcinoma of the breast. Diagn Cytopathol 2010;38:235-8. [PMID: 19790246 DOI: 10.1002/dc.21181] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
230 Conconi D, Chiappa V, Perego P, Redaelli S, Bovo G, Lavitrano M, Milani R, Dalprà L, Lissoni AA. Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential. Oncol Rep 2017;37:41-7. [PMID: 28004108 DOI: 10.3892/or.2016.5274] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
231 Mommers EC, van Diest PJ, Leonhart AM, Meijer CJ, Baak JP. Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast. Hum Pathol 1998;29:1539-45. [PMID: 9865845 DOI: 10.1016/s0046-8177(98)90028-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
232 Carroll RS, Zhang J, Chauncey BW, Chantziara K, Frosch MP, Black PM. Apoptosis in astrocytic neoplasms. Acta neurochir 1997;139:845-50. [DOI: 10.1007/bf01411402] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
233 Sasatomi E, Tokunaga O, Miyazaki K. Spontaneous apoptosis in gallbladder carcinoma: Relationships with clinicopathologic factors, expression of E-cadherin,bcl-2 protooncogene, and p53 oncosuppressor gene. Cancer 1996;78:2101-10. [DOI: 10.1002/(sici)1097-0142(19961115)78:10<2101::aid-cncr10>3.0.co;2-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
234 Mita AC, Mita MM, Rowinsky EK. Development of Rationally Designed, Target-Based Agents for the Treatment of Advanced Colorectal Cancer. Clinical Colorectal Cancer 2004;4:107-23. [DOI: 10.3816/ccc.2004.n.014] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
235 Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Breast cancer biomarkers. Adv Clin Chem 2005;40:99-125. [PMID: 16355921 DOI: 10.1016/s0065-2423(05)40003-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
236 Rochaix P, Krajewski S, Reed JC, Bonnet F, Voigt JJ, Brousset P. In vivo patterns of Bcl-2 family protein expression in breast carcinomas in relation to apoptosis. J Pathol 1999;187:410-5. [PMID: 10398099 DOI: 10.1002/(SICI)1096-9896(199903)187:4<410::AID-PATH266>3.0.CO;2-F] [Cited by in Crossref: 41] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
237 Liu JR, Fletcher B, Page C, Hu C, Nunez G, Baker V. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol Oncol 1998;70:398-403. [PMID: 9790794 DOI: 10.1006/gyno.1998.5125] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 2.3] [Reference Citation Analysis]
238 Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG, McLean CA, Callagy G, Green AR, Ellis I, Gelmon K, Turashvili G, Leung S, Aparicio S, Huntsman D, Caldas C, Pharoah P. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 2010;103:668-75. [PMID: 20664598 DOI: 10.1038/sj.bjc.6605736] [Cited by in Crossref: 182] [Cited by in F6Publishing: 173] [Article Influence: 16.5] [Reference Citation Analysis]
239 Yin H, Okada N, Takagi M. Apoptosis and apoptotic-related factors in mucoepidermoid carcinoma of the oral minor salivary glands. Pathol Int 2000;50:603-9. [DOI: 10.1046/j.1440-1827.2000.01091.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
240 Kumaravel B, Arihiro K, Kaneko M, Fujii S, Inai K. Expression ofbcl-2 protein in breast carcinoma with correlation to expression ofp53 protein and clinicopathological factors. Breast Cancer 1996;3:173-9. [DOI: 10.1007/bf02966981] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
241 Izawa H, Yonemitsu N, Shin T, Sugihara H. Histopathological analysis of apoptosis, and expression of p53, bcl-2, bax, and Ki-67 in laryngeal squamous cell carcinomas and dysplasia. Auris Nasus Larynx 1999;26:317-30. [DOI: 10.1016/s0385-8146(99)00005-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
242 Elkak AE, Kirkpatrick K, Mears L, Wells C, Ghilchik M, Newbold R, Mokbel K. Telomerase activity and Bcl-2 expression in human breast cancer. Eur J Surg Oncol. 2002;28:14-18. [PMID: 11869007 DOI: 10.1053/ejso.2001.1186] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
243 Gollapudi L, Oblinger MM. Estrogen and NGF synergistically protect terminally differentiated, ERα-transfected PC12 cells from apoptosis. J Neurosci Res 1999;56:471-81. [DOI: 10.1002/(sici)1097-4547(19990601)56:5<471::aid-jnr3>3.0.co;2-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
244 Benoit RM, Eiseman J, Jacobs SC, Kyprianou N. Reversion of human prostate tumorigenic growth by azatyrosine. Urology 1995;46:370-7. [PMID: 7660512 DOI: 10.1016/S0090-4295(99)80222-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
245 Bandoh N, Hayashi T, Kishibe K, Takahara M, Imada M, Nonaka S, Harabuchi Y. Prognostic value of p53 mutations, bax, and spontaneous apoptosis in maxillary sinus squamous cell carcinoma. Cancer. 2002;94:1968-1980. [PMID: 11932899 DOI: 10.1002/cncr.10388] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
246 Labi V, Erlacher M. How cell death shapes cancer. Cell Death Dis 2015;6:e1675. [PMID: 25741600 DOI: 10.1038/cddis.2015.20] [Cited by in Crossref: 132] [Cited by in F6Publishing: 122] [Article Influence: 22.0] [Reference Citation Analysis]
247 Daidone MG, Veneroni S, Benini E, Tomasic G, Coradini D, Mastore M, Brambilla C, Ferrari L, Silvestrini R. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. Int J Cancer 1999;84:580-6. [PMID: 10567902 DOI: 10.1002/(sici)1097-0215(19991222)84:6<580::aid-ijc7>3.0.co;2-w] [Cited by in Crossref: 35] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
248 Dan'ura T, Kawai A, Morimoto Y, Naito N, Yoshida A, Inoue H. Apoptosis and expression of its regulatory proteins in soft tissue sarcomas. Cancer Letters 2002;178:167-74. [DOI: 10.1016/s0304-3835(01)00836-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
249 Wu J, Shao Z, Shen Z, Lu J, Han Q, Fontana JA, Barsky SH. Significance of Apoptosis and Apoptotic-Related Proteins, Bcl-2, and Bax in Primary Breast Cancer. Breast Journal 2000;6:44-52. [DOI: 10.1046/j.1524-4741.2000.98094.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
250 Binder C, Marx D, Overhoff R, Binder L, Schauer A, Hiddemann W. Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Annals of Oncology 1995;6:1005-10. [DOI: 10.1093/oxfordjournals.annonc.a059064] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 1.4] [Reference Citation Analysis]
251 Ohbu M, Saegusa M, Kobayashi N, Tsukamoto H, Mieno H, Kakita A, Okayasu I. Expression ofbcl-2 protein in esophageal squamous cell carcinomas and its association with lymph node metastasis. Cancer 1997;79:1287-93. [DOI: 10.1002/(sici)1097-0142(19970401)79:7<1287::aid-cncr3>3.0.co;2-e] [Cited by in Crossref: 28] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
252 Sierra A, Castellsague X, Escobedo A, Moreno A, Drudis T, Fabra A. Synergistic cooperation between c-Myc and Bcl-2 in lymph node progression of T1 human breast carcinomas. Breast Cancer Res Treat 1999;54:39-45. [PMID: 10369079 DOI: 10.1023/a:1006120006471] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
253 Green JA, Berns EM, Coens C, van Luijk I, Thompson-Hehir J, van Diest P, Verheijen RH, van de Vijver M, van Dam P, Kenter GG, Tjalma W, Ewing PC, Teodorovic I, Vergote I, van der Burg ME; EORTC Gynaecological Cancer Group. Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). Eur J Cancer 2006;42:2539-48. [PMID: 16965910 DOI: 10.1016/j.ejca.2006.06.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
254 Bodner K, Bodner-adler B, Kimberger O, Czerwenka K, Mayerhofer K. Bcl-2 Receptor Expression in Patients With Uterine Smooth Muscle Tumors: An Immunohistochemical Analysis Comparing Leiomyoma, Uterine Smooth Muscle Tumor of Uncertain Malignant Potential, and Leiomyosarcoma. Journal of the Society for Gynecologic Investigation 2016;11:187-91. [DOI: 10.1016/j.jsgi.2003.10.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
255 Lacle MM, van der Pol C, Witkamp A, van der Wall E, van Diest PJ. Prognostic value of mitotic index and Bcl2 expression in male breast cancer. PLoS One 2013;8:e60138. [PMID: 23573235 DOI: 10.1371/journal.pone.0060138] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
256 Walker C, Robertson L, Myskow M, Dixon G. Expression of the BCL-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas. Br J Cancer 1995;72:164-9. [PMID: 7599047 DOI: 10.1038/bjc.1995.295] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 1.5] [Reference Citation Analysis]
257 Grimminger PP, Schneider PM, Metzger R, Vallböhmer D, Danenberg KD, Danenberg PV, Hölscher AH, Brabender J. The prognostic role of Bcl-2 mRNA expression in curatively resected non-small cell lung cancer (NSCLC). Lung Cancer 2010;70:82-7. [PMID: 20064672 DOI: 10.1016/j.lungcan.2009.12.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
258 Calastretti A, Bevilacqua A, Ceriani C, Viganò S, Zancai P, Capaccioli S, Nicolin A. Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase. Oncogene. 2001;20:6172-6180. [PMID: 11593425 DOI: 10.1038/sj.onc.1204751] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
259 Heidenberg HB, Bauer JJ, Mcleod DG, Moul JW, Srivastava S. The role of the p53 tumor suppressor gene in prostate cancer: A possible biomarker? Urology 1996;48:971-9. [DOI: 10.1016/s0090-4295(96)00365-2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
260 El Etreby MF, Liang Y, Wrenn RW, Schoenlein PV. Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 1998;51:149-168. [PMID: 9879777 DOI: 10.1023/a:1006078032287] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
261 Matsuyoshi S, Shimada K, Nakamura M, Ishida E, Konishi N. Bcl-2 phosphorylation has pathological significance in human breast cancer. Pathobiology 2006;73:205-12. [PMID: 17119350 DOI: 10.1159/000096022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
262 Tomita Y, Bilim V, Kawasaki T, Takahashi K, Okan I, Magnusson KP, Wiman KG. Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53. Int J Cancer 1996;66:322-5. [DOI: 10.1002/(sici)1097-0215(19960503)66:3<322::aid-ijc9>3.0.co;2-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
263 Borner MM, Brousset P, Pfanner-Meyer B, Bacchi M, Vonlanthen S, Hotz MA, Altermatt HJ, Schlaifer D, Reed JC, Betticher DC. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer 1999;79:952-8. [PMID: 10070896 DOI: 10.1038/sj.bjc.6690152] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 2.8] [Reference Citation Analysis]
264 Friedman M, Grey P, Venkatesan TK, Bloch I, Chawla P, Caldarelli DD, Coon JS. Prognostic significance of Bcl-2 expression in localized squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol 1997;106:445-50. [PMID: 9199601 DOI: 10.1177/000348949710600601] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 1.4] [Reference Citation Analysis]
265 Berardo MD, Elledge RM, Moor CD, Clark GM, Osborne CK, Allred DC. bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 1998;82:1296-302. [DOI: 10.1002/(sici)1097-0142(19980401)82:7<1296::aid-cncr12>3.0.co;2-1] [Cited by in Crossref: 75] [Article Influence: 3.3] [Reference Citation Analysis]
266 Kashyap D, Garg VK, Goel N. Intrinsic and extrinsic pathways of apoptosis: Role in cancer development and prognosis. Adv Protein Chem Struct Biol 2021;125:73-120. [PMID: 33931145 DOI: 10.1016/bs.apcsb.2021.01.003] [Reference Citation Analysis]
267 Coradini D, Pellizzaro C, Veneroni S, Ventura L, Daidone MG. Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. Br J Cancer 2002;87:1105-11. [PMID: 12402149 DOI: 10.1038/sj.bjc.6600556] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 2.3] [Reference Citation Analysis]
268 Kim K, Chie EK, Han W, Noh DY, Park IA, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Prognostic value of p53 and bcl-2 expression in patients treated with breast conservative therapy. J Korean Med Sci 2010;25:235-9. [PMID: 20119576 DOI: 10.3346/jkms.2010.25.2.235] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
269 Reed JC, Miyashita T, Takayama S, Wang H, Sato T, Krajewski S, Aimé-sempé C, Bodrug S, Kitada S, Hanada M. BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996;60:23-32. [DOI: 10.1002/(sici)1097-4644(19960101)60:1<23::aid-jcb5>3.0.co;2-5] [Cited by in Crossref: 318] [Article Influence: 12.7] [Reference Citation Analysis]
270 Zaha DC. Significance of immunohistochemistry in breast cancer. World J Clin Oncol. 2014;5:382-392. [PMID: 25114853 DOI: 10.5306/wjco.v5.i3.382.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
271 Makris A, Allred D, Powles T, Dowsett M, Fernando I, Trott P, Ashley S, Ormerod M, Titley J, Osborne C. Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat 1997;44:65-74. [DOI: 10.1023/a:1005717924761] [Cited by in Crossref: 40] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
272 Koshida Y, Saegusa M, Okayasu I. Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. Br J Cancer. 1997;75:367-373. [DOI: 10.1038/bjc.1997.60] [Cited by in Crossref: 60] [Cited by in F6Publishing: 66] [Article Influence: 2.5] [Reference Citation Analysis]
273 Brimmell M, Burns JS, Munson P, McDonald L, O'Hare MJ, Lakhani SR, Packham G. High level expression of differentially localized BAG-1 isoforms in some oestrogen receptor-positive human breast cancers. Br J Cancer 1999;81:1042-51. [PMID: 10576663 DOI: 10.1038/sj.bjc.6690805] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 2.3] [Reference Citation Analysis]
274 Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000;89:2145-52. [DOI: 10.1002/1097-0142(20001201)89:11<2145::aid-cncr1>3.0.co;2-s] [Cited by in Crossref: 112] [Article Influence: 5.3] [Reference Citation Analysis]
275 Friedrich K, Dimmer V, Haroske G, Loßnitzer A, Kasper M, Theissig F, Kunze K. Expression of p53 and bcl-2 in correlation to clinicopathological parameters, hormone receptor status and DNA ploidy in breast cancers. Pathology - Research and Practice 1995;191:1114-21. [DOI: 10.1016/s0344-0338(11)80656-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
276 Quinn CM, Ostrowski JL, Harkins L, Rice AJ, Loney DP. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins. Histopathology 1998;33:531-6. [PMID: 9870147 DOI: 10.1046/j.1365-2559.1998.00505.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
277 Honma N, Horii R, Ito Y, Saji S, Younes M, Iwase T, Akiyama F. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy. BMC Cancer 2015;15:698. [PMID: 26472348 DOI: 10.1186/s12885-015-1686-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
278 Collecchi P, Baldini E, Giannessi P, Naccarato AG, Passoni A, Gardin G, Roncella M, Evangelista G, Bevilacqua G, Conte PF. Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers. Eur J Cancer 1998;34:1701-4. [PMID: 9893655 DOI: 10.1016/s0959-8049(98)00213-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
279 Zhu CJ, Li YB, Wong MC. Expression of antisense bcl-2 cDNA abolishes tumorigenicity and enhances chemosensitivity of human malignant glioma cells. J Neurosci Res 2003;74:60-6. [PMID: 13130506 DOI: 10.1002/jnr.10722] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
280 Saegusa M, Takano Y, Hashimura M, Shoji Y, Okayasu I. The possible role of bcl-2 expression in the progression of tumors of the uterine cervix. Cancer 1995;76:2297-303. [PMID: 8635035 DOI: 10.1002/1097-0142(19951201)76:11<2297::aid-cncr2820761118>3.0.co;2-b] [Cited by in Crossref: 52] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
281 Moore, Ohene‐fianko, Garcia, Chakrabarti. Apoptosis in thyroid neoplasms: relationship with p53 and bcl‐2 expression. Histopathology 2001;32:35-42. [DOI: 10.1046/j.1365-2559.1998.00319.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
282 Luna-moré S, De Los Santos F, Bretón J, Cañadas M. Estrogen and Progesterone Receptors, C-ERBB-2, p53, and BCL-2 in Thirty-three Invasive Micropapillary Breast Carcinomas. Pathology - Research and Practice 1996;192:27-32. [DOI: 10.1016/s0344-0338(96)80126-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
283 Bargou RC, Wagener C, Bommert K, Mapara MY, Daniel PT, Arnold W, Dietel M, Guski H, Feller A, Royer HD, Dörken B. Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest 1996;97:2651-9. [PMID: 8647960 DOI: 10.1172/JCI118715] [Cited by in Crossref: 124] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
284 Mandavilli SR, Cartun RW, Ricci A, Tsongalis GJ. Immunohistochemical Evaluation of Genetic and Epigenetic Factors in Primary Breast Cancers. Journal of Histotechnology 2013;20:27-30. [DOI: 10.1179/his.1997.20.1.27] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
285 Albogami SM, Asiri Y, Asiri A, Alnefaie AA, Alnefaie S. Effects of neoadjuvant therapies on genetic regulation of targeted pathways in ER+ primary ductal breast carcinoma: A meta-analysis of microarray datasets. Saudi Pharm J 2021;29:656-69. [PMID: 34400859 DOI: 10.1016/j.jsps.2021.04.027] [Reference Citation Analysis]
286 Moulder SL, Symmans WF, Booser DJ, Madden TL, Lipsanen C, Yuan L, Brewster AM, Cristofanilli M, Hunt KK, Buchholz TA, Zwiebel J, Valero V, Hortobagyi GN, Esteva FJ. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res 2008;14:7909-16. [PMID: 19047121 DOI: 10.1158/1078-0432.CCR-08-1104] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
287 Buglioni S, D'agnano I, Cosimelli M, Vasselli S, D'angelo C, Tedesco M, Zupi G, Mottolese M. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: Independent prognostic role of p53 and bcl-2. Int J Cancer 1999;84:545-52. [DOI: 10.1002/(sici)1097-0215(19991222)84:6<545::aid-ijc1>3.0.co;2-2] [Cited by in Crossref: 71] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
288 McConkey DJ, Zhivotovsky B, Orrenius S. Apoptosis--molecular mechanisms and biomedical implications. Mol Aspects Med. 1996;17:1-110. [PMID: 8783196 DOI: 10.1016/0098-2997(95)00006-2] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 3.2] [Reference Citation Analysis]
289 Murillo-Ortiz B, Astudillo-De la Vega H, Castillo-Medina S, Malacara JM, Benitez-Bribiesca L. Telomerase activity, estrogen receptors (alpha, beta), Bcl-2 expression in human breast cancer and treatment response. BMC Cancer 2006;6:206. [PMID: 16911782 DOI: 10.1186/1471-2407-6-206] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
290 Park CS, Cho K, Bae DR, Joo NE, Kim HH, Mabasa L, Fowler AW. Methyl-donor nutrients inhibit breast cancer cell growth. In Vitro Cell Dev Biol Anim 2008;44:268-72. [PMID: 18498022 DOI: 10.1007/s11626-008-9096-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
291 Zoeller JJ, Vagodny A, Taneja K, Tan BY, O'Brien N, Slamon DJ, Sampath D, Leverson JD, Bronson RT, Dillon DA, Brugge JS. Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo. Mol Cancer Ther 2019;18:1115-26. [PMID: 30962322 DOI: 10.1158/1535-7163.MCT-18-0743] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
292 Grizzle WE, Myers RB, Marine U. The Use of Biomarker Expression to Characterize Neoplastic Processes. Biotechnic & Histochemistry 2009;72:96-104. [DOI: 10.3109/10520299709082218] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
293 Sakakura C, Sweeney EA, Shirahama T, Igarashi Y, Hakomori S, Tsujimoto H, Imanishi T, Ogaki M, Ohyama T, Yamazaki J, Hagiwara A, Yamaguchi T, Sawai K, Takahashi T. Overexpression ofBax sensitizes breast cancer MCF-7 cells to cisplatin and etoposide. Surg Today 1997;27:676-9. [DOI: 10.1007/bf02388231] [Cited by in Crossref: 24] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
294 Palazzo JP, Kafka NJ, Grasso L, Chakrani F, Hanau C, Cuesta KH, Mercer WE. The role of p53, p21WAF1/C1PI, and bcl-2 in radioresistant colorectal carcinoma. Hum Pathol 1997;28:1189-95. [PMID: 9343326 DOI: 10.1016/s0046-8177(97)90257-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
295 Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, Turkel G, Polverini PJ, Goldberg ID, Rosen EM. Expression of interleukin-1? in human breast carcinoma. Cancer 1997;80:421-34. [DOI: 10.1002/(sici)1097-0142(19970801)80:3<421::aid-cncr10>3.0.co;2-z] [Cited by in Crossref: 103] [Cited by in F6Publishing: 69] [Article Influence: 4.3] [Reference Citation Analysis]
296 Reed JC. Bcl-2 Family Proteins and the Hormonal Control of Cell Life and Death in Normalcy and Neoplasia. Elsevier; 1997. pp. 99-138. [DOI: 10.1016/s0083-6729(08)60705-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
297 Starcevic SL, Elferink C, Novak RF. Progressive Resistance to Apoptosis in a Cell Lineage Model of Human Proliferative Breast Disease. JNCI Journal of the National Cancer Institute 2001;93:776-82. [DOI: 10.1093/jnci/93.10.776] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
298 Liu HF, Liu WW, Fang DC, Men RP. Expression of bcl-2 protein in gastric carcinoma and its significance. World J Gastroenterol 1998; 4(3): 228-230 [PMID: 11819282 DOI: 10.3748/wjg.v4.i3.228] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 20] [Article Influence: 0.5] [Reference Citation Analysis]
299 Chiusa L, Margaria E, Pich A. Nuclear morphometry in male breast carcinoma: Association with cell proliferative activity, oncogene expression, DNA content and prognosis. Int J Cancer 2000;89:494-9. [DOI: 10.1002/1097-0215(20001120)89:6<494::aid-ijc5>3.0.co;2-l] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]